Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 2.4% - Here's Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price fell 2.4% during trading on Thursday . The stock traded as low as $5.13 and last traded at $5.27. 11,181,084 shares were traded during trading, a decline of 24% from the average session volume of 14,758,951 shares. The stock had previously closed at $5.40.

Wall Street Analyst Weigh In

Several research firms recently commented on RXRX. Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Needham & Company LLC cut their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Finally, Leerink Partners cut their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $7.60.

Recursion Pharmaceuticals Price Performance

The business has a 50-day simple moving average of $4.89 and a 200 day simple moving average of $6.32. The firm has a market cap of $2.00 billion, a P/E ratio of -3.22 and a beta of 0.84. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. During the same period in the previous year, the company earned ($0.39) EPS. The company's revenue for the quarter was up 7.2% on a year-over-year basis. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Ensign Peak Advisors Inc raised its position in shares of Recursion Pharmaceuticals by 0.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock worth $2,774,000 after acquiring an additional 1,300 shares in the last quarter. Farther Finance Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after buying an additional 1,353 shares during the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Recursion Pharmaceuticals by 7.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after buying an additional 1,875 shares during the last quarter. Clear Creek Financial Management LLC grew its stake in shares of Recursion Pharmaceuticals by 9.8% in the 1st quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock worth $113,000 after buying an additional 1,907 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after buying an additional 2,026 shares during the last quarter. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.